BACKGROUND: Infection is a common complication of ventricular-assist devices (VADs) and is associated with rehospitalization, thromboembolic events, VAD malfunction, delay in heart transplantation, and a high mortality rate. The objectives of this study were to investigate the frequency of fungal VAD infections and assess various risk factors and their effects on mortality as compared with bacterial VAD infections. METHODS: We conducted a retrospective chart review of patients with infected VADs at a single tertiary care center. The frequency, risk factors, and outcomes of fungal versus bacterial VAD infections were compared. RESULTS: Of the 300 patients who received a VAD, 108 (36%) developed VAD infection, including 85 bacterial and 23 fungal infections. Most common bacterial causes of infection were Staphylococcus aureus, coagulase-negative staphylococci, enterococci, and Pseudomonas aeuruginosa. The most common fungal etiologic agent was Candida albicans. Only the use of total parenteral nutrition was associated with the development of a fungal VAD infection in multivariate analysis (odds ratio, 6.95; 95% confidence interval, 1.71-28.16; P=.007). Patients who experienced fungal VAD infection were less likely to be cured (17.4% vs 56.3%; P=.001) and had greater mortality (91% vs 61%; P=.006), compared with those who experienced bacterial VAD infection. CONCLUSIONS: Fungi were responsible for approximately one-fifth of VAD infections and were associated with a mortality rate of 91%. Restriction of total parenteral nutrition use is essential in decreasing the rate of fungal VAD infection. Trials are needed for investigating the use of echinocandins or lipid formulations of amphotericin B for prevention and/or treatment of fungal VAD infection.
BACKGROUND:Infection is a common complication of ventricular-assist devices (VADs) and is associated with rehospitalization, thromboembolic events, VAD malfunction, delay in heart transplantation, and a high mortality rate. The objectives of this study were to investigate the frequency of fungal VAD infections and assess various risk factors and their effects on mortality as compared with bacterial VAD infections. METHODS: We conducted a retrospective chart review of patients with infected VADs at a single tertiary care center. The frequency, risk factors, and outcomes of fungal versus bacterial VAD infections were compared. RESULTS: Of the 300 patients who received a VAD, 108 (36%) developed VAD infection, including 85 bacterial and 23 fungal infections. Most common bacterial causes of infection were Staphylococcus aureus, coagulase-negative staphylococci, enterococci, and Pseudomonas aeuruginosa. The most common fungal etiologic agent was Candida albicans. Only the use of total parenteral nutrition was associated with the development of a fungal VAD infection in multivariate analysis (odds ratio, 6.95; 95% confidence interval, 1.71-28.16; P=.007). Patients who experienced fungal VAD infection were less likely to be cured (17.4% vs 56.3%; P=.001) and had greater mortality (91% vs 61%; P=.006), compared with those who experienced bacterial VAD infection. CONCLUSIONS: Fungi were responsible for approximately one-fifth of VAD infections and were associated with a mortality rate of 91%. Restriction of total parenteral nutrition use is essential in decreasing the rate of fungal VAD infection. Trials are needed for investigating the use of echinocandins or lipid formulations of amphotericin B for prevention and/or treatment of fungal VAD infection.
Authors: E A Rose; A C Gelijns; A J Moskowitz; D F Heitjan; L W Stevenson; W Dembitsky; J W Long; D D Ascheim; A R Tierney; R G Levitan; J T Watson; P Meier; N S Ronan; P A Shapiro; R M Lazar; L W Miller; L Gupta; O H Frazier; P Desvigne-Nickens; M C Oz; V L Poirier Journal: N Engl J Med Date: 2001-11-15 Impact factor: 91.245
Authors: O H Frazier; E A Rose; M C Oz; W Dembitsky; P McCarthy; B Radovancevic; V L Poirier; K A Dasse Journal: J Thorac Cardiovasc Surg Date: 2001-12 Impact factor: 5.209
Authors: Jeffrey A Morgan; Ranjit John; Vivek Rao; Alan D Weinberg; Brian J Lee; Pamela A Mazzeo; Margaret R Flannery; Jonathan M Chen; Mehmet C Oz; Yoshifumi Naka Journal: J Thorac Cardiovasc Surg Date: 2004-05 Impact factor: 5.209
Authors: Anna L Lazzell; Ashok K Chaturvedi; Christopher G Pierce; Deepthi Prasad; Priya Uppuluri; Jose L Lopez-Ribot Journal: J Antimicrob Chemother Date: 2009-07-07 Impact factor: 5.790
Authors: Robert S Poston; Shahid Husain; Damian Sorce; Ellieen Stanford; Shimon Kusne; Margaret Wagener; Bartley P Griffith; Robert L Kormos Journal: J Heart Lung Transplant Date: 2003-08 Impact factor: 10.247
Authors: Ishan Kamat; Harveen Lamba; Casey Hines-Munson; Samuel Hudson; Kenneth Liao; Kenneth L Muldrew; Sabrina Green; Austen Terwilliger; Heidi B Kaplan; Robert F Ramig; Anthony Maresso; Barbara W Trautner Journal: J Surg Res Date: 2021-11-27 Impact factor: 2.417
Authors: Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel Journal: Clin Infect Dis Date: 2015-12-16 Impact factor: 9.079
Authors: Delphine Héquet; Georg Kralidis; Thierry Carrel; Alexia Cusini; Christian Garzoni; Roger Hullin; Pascal R Meylan; Paul Mohacsi; Nicolas J Mueller; Frank Ruschitzka; Piergiorgio Tozzi; Christian van Delden; Maja Weisser; Markus J Wilhelm; Manuel Pascual; Oriol Manuel Journal: BMC Infect Dis Date: 2016-07-08 Impact factor: 3.090
Authors: Radoslav Zinoviev; Christopher K Lippincott; Sara C Keller; Nisha A Gilotra Journal: Open Forum Infect Dis Date: 2020-04-17 Impact factor: 3.835